Influence of androgen deprivation therapy on prostate volume in patients with prostate cancer undergoing prostate brachytherapy with permanent seed implantation

Ryuichi Mizuno, Tetsuo Monma, Masanori Hasegawa, Michio Kosugi, Toshio Ohashi, Kazuhito Toya, Atsunori Yorozu, Shiro Saito

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

(Objective) Enlarged prostate often causes pubic arch interference during needle insertion on transperineal interstitial permanent prostate brachytherapy. Pre-treatment hormonal therapy is necessary for downsizing the prostate gland in such cases. The degree of prostate downsizing with antiandrogen treatment before iodine 125 permanent seed implant brachytherapy and its relation to clinical as well as pathological parameters were assessed. (Methods) From September 2003 to March 2005, 110 patients underwent permanent seed implantation and 86 patients of all received antiandrogen depriviation prior to the treatment at our institute. Prostate volume was measured using transrectal ultrasound at the time of cancer diagnosis and before the seed implant. Correlations between prostate downsizing and clinical as well as pathological parameters were evaluated. (Results) Mean percent volume of the prostate after the size reduction with average of 6.0 months antiandrogen monotherapy, 7.7 months LHRH agoniost and 8.2 months maximum androgen blockage (MAB) was 83%, 63%, and 60%, respectively. Mann-Whitney U test revealed that the degree of prostate downsizing is significantly correlated with the prostate volume in patients with prostate cancer utilizing LHRH agonists. (Conclusions) Antiandrogen monotherapy can be an alternative for prostate downsizing before interstitial brachytherapy. Utilizing LHRH agonists or MAB is recommended for cases with larger gland volume.

Original languageEnglish
Pages (from-to)835-838
Number of pages4
JournalJapanese Journal of Urology
Volume97
Issue number7
Publication statusPublished - 2006 Nov
Externally publishedYes

Fingerprint

Brachytherapy
Androgens
Prostate
Prostatic Neoplasms
Seeds
Androgen Antagonists
Gonadotropin-Releasing Hormone
Therapeutics
Nonparametric Statistics
Iodine
Needles

Keywords

  • Brachytherapy
  • Prostate cancer
  • Prostate volume

ASJC Scopus subject areas

  • Urology

Cite this

Influence of androgen deprivation therapy on prostate volume in patients with prostate cancer undergoing prostate brachytherapy with permanent seed implantation. / Mizuno, Ryuichi; Monma, Tetsuo; Hasegawa, Masanori; Kosugi, Michio; Ohashi, Toshio; Toya, Kazuhito; Yorozu, Atsunori; Saito, Shiro.

In: Japanese Journal of Urology, Vol. 97, No. 7, 11.2006, p. 835-838.

Research output: Contribution to journalArticle

Mizuno, Ryuichi ; Monma, Tetsuo ; Hasegawa, Masanori ; Kosugi, Michio ; Ohashi, Toshio ; Toya, Kazuhito ; Yorozu, Atsunori ; Saito, Shiro. / Influence of androgen deprivation therapy on prostate volume in patients with prostate cancer undergoing prostate brachytherapy with permanent seed implantation. In: Japanese Journal of Urology. 2006 ; Vol. 97, No. 7. pp. 835-838.
@article{e5fde7981bfd4bb8aafcead059d3f92a,
title = "Influence of androgen deprivation therapy on prostate volume in patients with prostate cancer undergoing prostate brachytherapy with permanent seed implantation",
abstract = "(Objective) Enlarged prostate often causes pubic arch interference during needle insertion on transperineal interstitial permanent prostate brachytherapy. Pre-treatment hormonal therapy is necessary for downsizing the prostate gland in such cases. The degree of prostate downsizing with antiandrogen treatment before iodine 125 permanent seed implant brachytherapy and its relation to clinical as well as pathological parameters were assessed. (Methods) From September 2003 to March 2005, 110 patients underwent permanent seed implantation and 86 patients of all received antiandrogen depriviation prior to the treatment at our institute. Prostate volume was measured using transrectal ultrasound at the time of cancer diagnosis and before the seed implant. Correlations between prostate downsizing and clinical as well as pathological parameters were evaluated. (Results) Mean percent volume of the prostate after the size reduction with average of 6.0 months antiandrogen monotherapy, 7.7 months LHRH agoniost and 8.2 months maximum androgen blockage (MAB) was 83{\%}, 63{\%}, and 60{\%}, respectively. Mann-Whitney U test revealed that the degree of prostate downsizing is significantly correlated with the prostate volume in patients with prostate cancer utilizing LHRH agonists. (Conclusions) Antiandrogen monotherapy can be an alternative for prostate downsizing before interstitial brachytherapy. Utilizing LHRH agonists or MAB is recommended for cases with larger gland volume.",
keywords = "Brachytherapy, Prostate cancer, Prostate volume",
author = "Ryuichi Mizuno and Tetsuo Monma and Masanori Hasegawa and Michio Kosugi and Toshio Ohashi and Kazuhito Toya and Atsunori Yorozu and Shiro Saito",
year = "2006",
month = "11",
language = "English",
volume = "97",
pages = "835--838",
journal = "Japanese Journal of Urology",
issn = "0021-5287",
publisher = "Japanese Urological Association",
number = "7",

}

TY - JOUR

T1 - Influence of androgen deprivation therapy on prostate volume in patients with prostate cancer undergoing prostate brachytherapy with permanent seed implantation

AU - Mizuno, Ryuichi

AU - Monma, Tetsuo

AU - Hasegawa, Masanori

AU - Kosugi, Michio

AU - Ohashi, Toshio

AU - Toya, Kazuhito

AU - Yorozu, Atsunori

AU - Saito, Shiro

PY - 2006/11

Y1 - 2006/11

N2 - (Objective) Enlarged prostate often causes pubic arch interference during needle insertion on transperineal interstitial permanent prostate brachytherapy. Pre-treatment hormonal therapy is necessary for downsizing the prostate gland in such cases. The degree of prostate downsizing with antiandrogen treatment before iodine 125 permanent seed implant brachytherapy and its relation to clinical as well as pathological parameters were assessed. (Methods) From September 2003 to March 2005, 110 patients underwent permanent seed implantation and 86 patients of all received antiandrogen depriviation prior to the treatment at our institute. Prostate volume was measured using transrectal ultrasound at the time of cancer diagnosis and before the seed implant. Correlations between prostate downsizing and clinical as well as pathological parameters were evaluated. (Results) Mean percent volume of the prostate after the size reduction with average of 6.0 months antiandrogen monotherapy, 7.7 months LHRH agoniost and 8.2 months maximum androgen blockage (MAB) was 83%, 63%, and 60%, respectively. Mann-Whitney U test revealed that the degree of prostate downsizing is significantly correlated with the prostate volume in patients with prostate cancer utilizing LHRH agonists. (Conclusions) Antiandrogen monotherapy can be an alternative for prostate downsizing before interstitial brachytherapy. Utilizing LHRH agonists or MAB is recommended for cases with larger gland volume.

AB - (Objective) Enlarged prostate often causes pubic arch interference during needle insertion on transperineal interstitial permanent prostate brachytherapy. Pre-treatment hormonal therapy is necessary for downsizing the prostate gland in such cases. The degree of prostate downsizing with antiandrogen treatment before iodine 125 permanent seed implant brachytherapy and its relation to clinical as well as pathological parameters were assessed. (Methods) From September 2003 to March 2005, 110 patients underwent permanent seed implantation and 86 patients of all received antiandrogen depriviation prior to the treatment at our institute. Prostate volume was measured using transrectal ultrasound at the time of cancer diagnosis and before the seed implant. Correlations between prostate downsizing and clinical as well as pathological parameters were evaluated. (Results) Mean percent volume of the prostate after the size reduction with average of 6.0 months antiandrogen monotherapy, 7.7 months LHRH agoniost and 8.2 months maximum androgen blockage (MAB) was 83%, 63%, and 60%, respectively. Mann-Whitney U test revealed that the degree of prostate downsizing is significantly correlated with the prostate volume in patients with prostate cancer utilizing LHRH agonists. (Conclusions) Antiandrogen monotherapy can be an alternative for prostate downsizing before interstitial brachytherapy. Utilizing LHRH agonists or MAB is recommended for cases with larger gland volume.

KW - Brachytherapy

KW - Prostate cancer

KW - Prostate volume

UR - http://www.scopus.com/inward/record.url?scp=33846070086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846070086&partnerID=8YFLogxK

M3 - Article

C2 - 17154026

AN - SCOPUS:33846070086

VL - 97

SP - 835

EP - 838

JO - Japanese Journal of Urology

JF - Japanese Journal of Urology

SN - 0021-5287

IS - 7

ER -